glp-3 retatrutide GLP3 – Reta (10mg) |

McCallum RW, Lembo A, Esfandyari T, Bhandari BR, Ejskjaer N, Cosentino C, et al

The litigation further alleges that pharmaceutical manufacturers continued aggressively marketing GLP-1 medications despite growing concerns surrounding delayed gastric emptying, intestinal motility disorders, and reported optic nerve injuries

The latter is probably the result on an exacerbation of a baseline psychiatric condition rather than a de novo process (312)

Pareek N, Fleisher DR, Abell T

In fact, higher doses of GLP-1 medications in general are more likely to cause these side effects

This is standard practice for individuals with naturally dark skin living at high latitudes, and the same principle applies to pharmacologically induced pigmentation.